Titan Securities Reports Q2 Consolidated PAT of Rs 5.02 Crore

Consolidated PAT stood at Rs 5.02 crore, while standalone revenue was Rs 0.62 crore for the quarter ending September 30, 2026.

Reader Takeaway: Consolidated earnings are driven by associate profits; standalone operations remain minor contributors to the overall group performance.

What just happened

Titan Securities Ltd released its financial results for the quarter and half-year ended September 30, 2026. The company reported a significant difference between its standalone and consolidated figures, reflecting its status as a holding firm. For the quarter, the company recorded a consolidated PAT of Rs 5.02 crore, compared to a standalone PAT of Rs 0.30 crore. Total standalone revenue for the same period was Rs 0.62 crore.

Why this matters

The group's overall profitability is tied directly to its strategic investments. The consolidated results include the share of profits from two key associates: Titan Biotech Limited and Peptech Biosciences Limited. Shareholders must focus on these associates rather than the parent company's standalone business to gauge true financial health.

Auditor's Review

The statutory auditors, Goyal Nagpal & Co., performed a limited review of both standalone and consolidated statements. They issued an unmodified conclusion, confirming that the financial statements comply with Indian Accounting Standards. The review was conducted under SRE 2410 guidelines.

Governance Update

The Board of Directors approved the financial results on November 5, 2026. The company remains in compliance with SEBI Regulation 33 concerning Listing Obligations and Disclosure Requirements.

What to track next

Investors should closely watch the financial disclosures of Titan Biotech and Peptech Biosciences. Any volatility or changes in dividend policies at these associate companies will directly impact the consolidated earnings profile of Titan Securities moving forward.